AstraZeneca Pharma India Limited has filed a regulatory compliance certificate with stock exchanges, confirming its adherence to SEBI dematerialization regulations. The pharmaceutical company submitted the certificate to both BSE Limited and National Stock Exchange of India on March 13, 2026, through Company Secretary and Compliance Officer Tanya Sanish.

Regulatory Compliance Certificate Details

The compliance certificate was issued by Integrated Registry Management Services Private Limited, the company's Registrar and Transfer Agent, on March 3, 2026. The certificate specifically addresses compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, covering the period from February 1, 2026 to February 28, 2026.

Compliance Confirmations

The Registrar and Transfer Agent confirmed compliance with three key regulatory requirements within the mandated 15-day timeframe upon receipt of security certificates from depository participants:

• Securities comprised in dematerialized certificates are properly listed on relevant stock exchanges
• Physical certificates forwarded by participants have been mutilated and canceled
• Depository names have been substituted as registered owners in company records

Corporate Information

AstraZeneca Pharma India Limited operates from its corporate and registered office at Manyata Embassy Business Park, Bangalore, with manufacturing facilities located at Bellary Road, Yelahanka. The company maintains its commitment to regulatory compliance through systematic adherence to SEBI guidelines and timely submissions to stock exchanges.

The certificate submission represents standard regulatory practice, ensuring transparency in securities handling and maintaining investor confidence in the dematerialization process. The company's proactive approach to regulatory compliance demonstrates its commitment to maintaining proper corporate governance standards.

AstraZeneca Pharma India Limited has announced the appointment of Mrs. Sandhya Tejaswini Amanna as Director - Legal, effective March 18, 2026. The appointment was approved by the Board of Directors based on the recommendation of the Nomination and Remuneration Committee, as disclosed under Regulation 30 of SEBI Listing Regulations.

Appointment Details

The company has classified this as a Senior Management Personnel position under SEBI Listing Regulations. Mrs. Amanna's appointment represents a full-time employment arrangement with the pharmaceutical company.

Professional Background

Mrs. Sandhya Amanna brings extensive legal expertise spanning over two decades across manufacturing, FMCG, and pharmaceutical sectors. Her comprehensive experience encompasses multiple leadership responsibilities in legal advisory, compliance, and governance functions.

As an in-house counsel, she has demonstrated expertise in:

• End-to-end contract management
• Dispute resolution and legal risk management
• Complex intellectual property litigation
• Compliance initiatives within pharmaceutical sector

Leadership Experience

In her previous role at Danone India, Mrs. Amanna served as Head of Legal, Compliance and Secretarial, where she drove the legal, compliance, and governance agenda for the organization. She collaborated closely with cross-functional leadership teams to manage legal risk, strengthen compliance frameworks, and support strategic business decisions.

Educational Qualifications

Mrs. Amanna holds an LLB degree from University of Mumbai and is an alumna of Government Law College, Mumbai. Her educational background provides a strong foundation for her legal expertise in the corporate sector.

Regulatory Compliance

The appointment disclosure was made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has provided comprehensive details as required under SEBI Circular No. HO/49/14/14(7)2025 - CFD-POD2/I/3762/2026 dated January 30, 2026.